Determination of Regulatory Review Period for Purposes of Patent Extension; MONOFERRIC

Determination of Regulatory Review Period for Purposes of Patent Extension; MONOFERRIC The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for MONOFERRIC and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product. Agency: Health and Human Services Department, Food and Drug Administration. Document type: Notice. Document number: 2026-20766. Official Federal Register document. Matter furnished by the National Archives Federal Register API. Notice Nearby is not the publisher of record for this item. Source: https://www.federalregister.gov/documents/2026/10/09/2026-20766/determination-of-regulatory-review-period-for-purposes-of-patent-extension-monoferric